NCT01058642View on ClinicalTrials.gov

Study to Assess the Efficacy, Safety, and Tolerability of ADL5747 in Participants With Postherpetic Neuralgia

PHASE2TerminatedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Postherpetic Neuralgia
Interventions
DRUG

ADL5747

DRUG

Placebo

DRUG

Pregabalin

Trial Locations (1)

33407-2450

Laszlo J. Mate, MD, West Palm Beach

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY